As a pioneer in the field of liver related elastography, FibroScan® is recognized worldwide as the non-invasive gold standard solution for liver fibrosis and liver steatosis assessment with more than 2,500 peer reviewed publications.
Our one-of-a-kind parameters
LSM by VCTE™ (Liver Stiffness Measurement by Vibration-Controlled Transient Elastography), CAP™ (controlled attenuation parameter) and SSM by VCTE™ (Spleen Stiffness Measurement) enable point of care, non-invasive diagnosis and monitoring.
LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness.1
2,250 peer-reviewed publications support the use of LSM by VCTE™.
CAP™ is unique, patented and validated for liver steatosis assessment.2,3
330 international and peer-reviewed articles support the use of CAP™.
SSM by VCTE™ is unique, patented and validated for portal hypertension assessment and can be used for risk stratification of patients with advanced chronic liver disease.4
100 peer-reviewed publications support the use of SSM by VCTE™.
2,500 peer-reviewed publications and more than 70 international guidelines evaluating, reporting or citing LSM by VCTE™ and CAP™.
VCTE™ can be used to accurately diagnose cirrhosis at an acceptable rate of false negatives and false positives in patients with chronic liver disease.
CAP™ is a point-of-care, standardized and reproducible technique, promising for the detection of liver steatosis.
TE is an established technique and is recommended as the initial assessment for significant liver fibrosis and cirrhosis (A1).
TE is a highly reproducible and user-friendly technique for assessing liver fibrosis in patients with chronic liver disease.
TE can be considered the non-invasive standard for the measurement of liver stiffness.
TE: Most widely used and validated technique for measurement of liver stiffness: standard to be beaten.
Vibration-controlled transient elastography (VCTE) is the most commonly used imaging-based fibrosis assessment method in the United States.
It has been validated in large cohorts worldwide in a spectrum of liver diseases, including hepatitis B, hepatitis C, fatty liver disease and autoimmune liver disorders, among others.